Skip to main content
Premium Trial:

Request an Annual Quote

Activiomics Lands $806K Investment

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – UK phosphoproteomics firm Activiomics today announced it has received a £500,000 ($806,715) investment, which it will use to further build partnerships with pharmaceutical and biotech firms and to identify novel biomarkers.

Leading the round was IP Group. Additional investors included IP Venture Fund and members of Activiomics' management.

The company, based in London, is a spinout of the Institute of Cancer, Barts and the London School of Medicine and Dentistry at Queen Mary, University of London. Its flagship technology called Targeted In-Depth Quantification of Cell Signaling, or TIQUAS, combines phosphoproteomics, mass spectrometry, and a proprietary database and software to investigate cell signaling pathways.

According to the firm, its technology has applications in biomarker and drug discovery in disease areas including oncology and inflammation. In December, Activiomics inked an agreement with biopharma firm UCB for the use of TIQUAS for the analysis and interpretation of cell-signaling pathway activity.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.